ZZ Biotech, LLC

zzbiotech.com

ZZ Biotech LLC is a clinical stage company developing innovative biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. ZZ Biotech was incepted in 2006 to focus on the development of 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. ZZ Biotech’s 3K3A-APC is a genetically engineered variant of recombinant APC, a serine protease. APC has two biochemical pathways in the body. APC exerts anticoagulant activity by inactivation of Factor Va and VIIIa, and it exerts cytoprotective activity primarily through interaction with the endothelial protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1). 3K3A-APC was designed through elegant biochemistry and molecular biology as a safer, “bio-better” version of APC, with greatly reduced anti-coagulant activity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

news image

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More

INDUSTRIAL IMPACT

TARA BIOSYSTEMS PARTNERS WITH SCIPHER MEDICINE®

TARA Biosystems | November 03, 2021

news image

TARA Biosystemsa, biotechnology company harnessing human biology and data to transform cardiac drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company matching patients with the most effective therapy. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies. Cardiac laminopathies, associated with mutations in the LMNA gene, can result in electrical and mechanical changes in the heart. Thes...

Read More

CELL AND GENE THERAPY

IXCELLS BIOTECHNOLOGIES SECURES STRATEGIC GROWTH INVESTMENT FROM GREAT POINT PARTNERS

iXCells Biotechnologies | September 30, 2022

news image

iXCells Biotechnologies a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell derived cellular models, today announced receiving a growth investment from Connecticut-based Great Point Partners a private investment firm focusing on the healthcare industry. “iXCells is delighted to join GPP’s portfolio of ...

Read More

STEMCYTE SUBMITTED ITS APPLICATION FOR A BIOLOGICS LICENSE (BLA) FOR ITS PRODUCT "HPC-CORD BLOOD" TO THE US FDA

Stemcyte | March 23, 2022

news image

On January 7th, 2022, the FDA received the BLA (Biologics License Application) for the "HPC-Cord Blood" product. On March 8th, 2022, StemCyte was formally informed that the submission was acceptable to join the biologics license quality review process. The "HPC-Cord Blood" is an umbilical cord blood hematopoietic stem cell product intended for unrelated donor hematopoietic progenitor cell transplantation procedures in patients with hematopoietic system disorder...

Read More
news image

INDUSTRIAL IMPACT

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More
news image

INDUSTRIAL IMPACT

TARA BIOSYSTEMS PARTNERS WITH SCIPHER MEDICINE®

TARA Biosystems | November 03, 2021

TARA Biosystemsa, biotechnology company harnessing human biology and data to transform cardiac drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company matching patients with the most effective therapy. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies. Cardiac laminopathies, associated with mutations in the LMNA gene, can result in electrical and mechanical changes in the heart. Thes...

Read More
news image

CELL AND GENE THERAPY

IXCELLS BIOTECHNOLOGIES SECURES STRATEGIC GROWTH INVESTMENT FROM GREAT POINT PARTNERS

iXCells Biotechnologies | September 30, 2022

iXCells Biotechnologies a high growth provider of cell-based products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with special focus on primary and induced pluripotent stem cell derived cellular models, today announced receiving a growth investment from Connecticut-based Great Point Partners a private investment firm focusing on the healthcare industry. “iXCells is delighted to join GPP’s portfolio of ...

Read More
news image

STEMCYTE SUBMITTED ITS APPLICATION FOR A BIOLOGICS LICENSE (BLA) FOR ITS PRODUCT "HPC-CORD BLOOD" TO THE US FDA

Stemcyte | March 23, 2022

On January 7th, 2022, the FDA received the BLA (Biologics License Application) for the "HPC-Cord Blood" product. On March 8th, 2022, StemCyte was formally informed that the submission was acceptable to join the biologics license quality review process. The "HPC-Cord Blood" is an umbilical cord blood hematopoietic stem cell product intended for unrelated donor hematopoietic progenitor cell transplantation procedures in patients with hematopoietic system disorder...

Read More